1. Home
  2. MDWD vs GCO Comparison

MDWD vs GCO Comparison

Compare MDWD & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • GCO
  • Stock Information
  • Founded
  • MDWD 2000
  • GCO 1924
  • Country
  • MDWD Israel
  • GCO United States
  • Employees
  • MDWD N/A
  • GCO N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • GCO Clothing/Shoe/Accessory Stores
  • Sector
  • MDWD Health Care
  • GCO Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • GCO Nasdaq
  • Market Cap
  • MDWD 230.6M
  • GCO 238.4M
  • IPO Year
  • MDWD 2014
  • GCO N/A
  • Fundamental
  • Price
  • MDWD $19.09
  • GCO $22.34
  • Analyst Decision
  • MDWD Strong Buy
  • GCO Hold
  • Analyst Count
  • MDWD 2
  • GCO 2
  • Target Price
  • MDWD $35.00
  • GCO $24.50
  • AVG Volume (30 Days)
  • MDWD 59.0K
  • GCO 359.0K
  • Earning Date
  • MDWD 08-13-2025
  • GCO 06-04-2025
  • Dividend Yield
  • MDWD N/A
  • GCO N/A
  • EPS Growth
  • MDWD N/A
  • GCO N/A
  • EPS
  • MDWD N/A
  • GCO N/A
  • Revenue
  • MDWD $19,213,000.00
  • GCO $2,341,438,000.00
  • Revenue This Year
  • MDWD $20.80
  • GCO $1.67
  • Revenue Next Year
  • MDWD $26.92
  • GCO $1.69
  • P/E Ratio
  • MDWD N/A
  • GCO N/A
  • Revenue Growth
  • MDWD N/A
  • GCO 1.85
  • 52 Week Low
  • MDWD $12.78
  • GCO $16.19
  • 52 Week High
  • MDWD $24.00
  • GCO $44.80
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 37.96
  • GCO 52.78
  • Support Level
  • MDWD $19.98
  • GCO $21.24
  • Resistance Level
  • MDWD $20.95
  • GCO $22.64
  • Average True Range (ATR)
  • MDWD 0.64
  • GCO 1.39
  • MACD
  • MDWD -0.38
  • GCO -0.06
  • Stochastic Oscillator
  • MDWD 0.29
  • GCO 36.51

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About GCO Genesco Inc.

Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.

Share on Social Networks: